文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

前列腺癌诊疗项目在商业保险公司间医疗必要性判定的差异

Variations in Medical Necessity Determinations Across Commercial Insurance Carriers for Prostate Cancer Procedures.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-07-30

研究分析了美国51个州及哥伦比亚特区83份商业保险医疗政策,评估水凝胶间隔物、氟昔洛韦PET和低体积转移性前列腺癌调强放疗的覆盖判定差异。结果显示各州覆盖政策差异广泛,使用外部利用管理公司的保险公司判定更为严格。作者认为需要更一致的医疗必要性判定方法以减少因居住地和年龄导致的服务可及性不平等。

要点

  • 水凝胶间隔物在9个州被判定为医疗必要,22个州判定为非必要,8个州混合覆盖,12个州无公开政策。
  • 氟昔洛韦PET的最低PSA要求各州不同:9个州要求2 ng/mL,17个州要求1 ng/mL,7个州要求任何最低PSA,12个州混合覆盖,6个州无公开政策。
  • 低体积转移性前列腺癌的调强放疗在17个州被判定为医疗必要,7个州为非必要,27个州未明确说明。

核心结论

  • 商业保险医疗政策对FDA批准且Medicare覆盖的新颖前列腺癌诊疗项目的医疗必要性判定存在广泛差异。
  • 这些数据提示需要更一致的医疗必要性判定方法,以减少因居住地和年龄导致患者获得癌症诊疗服务的不平等。

研究设计与样本

  • 基于2020年美国政府采购局(GAO-21-34)报告确定各州主要商业保险公司,分析2021年1月1日至2021年1月31日公开医疗政策。
  • 共分析51个州及哥伦比亚特区的83份商业医疗政策,评估3项广泛认可的诊疗项目:水凝胶间隔物、氟昔洛韦-正电子发射断层扫描(PET)、低体积转移性前列腺癌的调强放疗。

主要发现

  • 水凝胶间隔物在9个州判定为医疗必要,8个州混合覆盖,22个州判定为非医疗必要,12个州无公开政策。
  • 氟昔洛韦-PET的最低前列腺特异性抗原(PSA)要求:9个州要求2 ng/mL,17个州要求1 ng/mL,7个州要求任何最低PSA,12个州混合覆盖,6个州无公开政策。
  • 低体积转移性前列腺癌的调强放疗在17个州判定为医疗必要,7个州判定为非必要,27个州未说明。
  • 保险公司常使用外部利用管理公司如AIM-Healthcare和Evicore Healthcare,这些判定比未使用利用管理的保险公司更为严格。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Variation in commercial insurance coverage may lead to disparity in access to quality cancer care. We evaluated commercial insurance coverage determinations to assess the degree of variation across a national sample. METHODS AND MATERIALS: We identified the predominant carrier of commercial insurance in each state based on the 2020 US Government Accounting Office (GAO-21-34) report on insurance. For each state, publicly available medical policies from January 1, 2021 to January 31, 2021 were analyzed for coverage of 3 widely accepted procedures: hydrogel spacer, fluciclovine- positron emission tomography (PET), and intensity modulated radiation in low volume metastatic prostate cancer. RESULTS: We analyzed 83 commercial medical policies across 51 states and District of Columbia. There was widespread variation in coverage policy. Hydrogel spacer was determined medically necessary in 9 states, mixed coverage in 8, not medically necessary in 22, and no available public policy in 12. Use of fluciclovine-PET required a minimum prostate specific antigen level of 2 ng/mL in 9 states, 1 ng/mL in 17, any minimum prostate specific antigen in 7, mixed coverage in 12, and no publicly available policy in 6. Intensity modulated radiation in low volume metastatic prostate cancer was medically necessary in 17 states, not necessary in 7, and not stated in 27. Insurance carriers often used external utilization management companies such as AIM-Healthcare and Evicore Healthcare. These determinations were more restrictive than carriers which did not use utilization management. CONCLUSIONS: Commercial medical policies vary widely in medical necessity determinations for novel prostate cancer treatment procedures that are Food and Drug-approved and covered by Medicare. These data suggest a need for more consistent methodology for medical necessity determination to mitigate the current state where patients have unequal access to cancer procedures due to the location of residence and age.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Shen X, Spratt DE, Dusetzina SB, et al. Variations in Medical Necessity Determinations Across Commercial Insurance Carriers for Prostate Cancer Procedures. Int J Radiat Oncol Biol Phys. 2022. PMID: 35918053. doi:10.1016/j.ijrobp.2022.07.1839

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。